Home › Funds › BAKER BROS. ADVISORS LP › IONS
BAKER BROS. ADVISORS LP position in IONS
IONIS PHARMACEUTICALS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 1,023,864 shares of IONS (IONIS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$45.7M, representing 0.22% of its reported portfolio and ranking #30 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed IONS holdings in 8 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's IONS position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in IONS in Q3 2024 at 223,470 shares (US$9.0M). The position peaked in Q2 2026 at 2,047,727 shares, worth US$162.4M. Across 8 filings, BAKER BROS. ADVISORS LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 1,023,864 shares valued at US$45.7M — a reduction of -1,023,863 shares quarter over quarter.. Notable position changes include a 60% increase in Q4 2024 (shares fell 14% over the following quarter), a 216% increase in Q4 2025 (shares fell 5% over the following quarter), a 50% trim in Q3 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 223.47K | $8.95M | New |
| Q4 2024 | 357.92K | $12.51M | Add |
| Q1 2025 | 357.92K | $10.80M | Hold |
| Q3 2025 | 566.80K | $37.08M | New |
| Q4 2025 | 1.79M | $141.75M | Add |
| Q1 2026 | 2.05M | $153.76M | Add |
| Q2 2026 | 2.05M | $162.36M | Hold |
| Q3 2026 | 1.02M | $45.72M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IONS and 13F data
IONS (IONIS PHARMACEUTICALS INC) is a Health Care company. 27 other funds we track also report a position in IONS — the largest reported positions include Two Sigma Investments (US$300.4M), TWO SIGMA ADVISERS, LP (US$241.5M), TENOR CAPITAL MANAGEMENT Co., L.P. (US$107.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IONS
- Two Sigma Investments 6.73M sh · $300.38M · Q3 2026
- TWO SIGMA ADVISERS, LP 3.05M sh · $241.45M · Q4 2025
- TENOR CAPITAL MANAGEMENT Co., L.P. 97.68M sh · $107.83M · Q3 2026
- Tweedy, Browne Co LLC 1.79M sh · $80.08M · Q3 2026
- GROUPAMA ASSET MANAGMENT 937.08K sh · $75.20M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 60.00M sh · $65.97M · Q3 2026
- HIGHBRIDGE CAPITAL MANAGEMENT LLC 57.59M sh · $64.13M · Q3 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held IONS?
BAKER BROS. ADVISORS LP has disclosed IONS holdings in 8 of the last 9 reported quarters, going back to Q3 2024.
What is BAKER BROS. ADVISORS LP's current position in IONS?
As of Q3 2026, BAKER BROS. ADVISORS LP holds 1.02M shares of IONS (IONIS PHARMACEUTICALS INC), valued at $45.72M, representing 0.22% of its reported portfolio and ranking #30.
Has BAKER BROS. ADVISORS LP been buying or selling IONS?
In the latest 13F filing (Q3 2026), BAKER BROS. ADVISORS LP reduced its position in IONS. The position peaked in Q2 2026 at 2.05M shares.
Which other funds hold IONS?
Other major institutional holders of IONS include Two Sigma Investments, TWO SIGMA ADVISERS, LP, TENOR CAPITAL MANAGEMENT Co., L.P., among 27 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.